Top Venlafaxine Brands: A Guide to Trusted Options

Venlafaxine, a widely recognized antidepressant, is available from numerous reputable brands, each offering its unique formulation to cater to diverse patient needs. Known for its efficacy in treating depression and anxiety disorders, venlafaxine is prescribed globally under various brand names. Among the top brands, some have gained recognition for their consistent quality and patient satisfaction. To discover a comprehensive list of the best brands for venlafaxine and learn more about their distinguishing features, read below.

Illustration of venlafaxine

Best brands of venlafaxine in 2025

Effexor XR

Effexor XR, produced by Pfizer Inc., remains a dominant force in the venlafaxine market, particularly in China, where it accounted for approximately 50% of the market share in terms of sales value in 2020. Despite entering the Chinese market later in 2001, Effexor XR has maintained its significant market presence. The product is an extended-release capsule of venlafaxine hydrochloride, used to treat various mental health conditions. Its market share and sales have been impacted by COVID-19, but the market is expected to grow as the pandemic is brought under control. Effexor XR's strong market position is a testament to its efficacy and reliability. For more information, you can visit the official Pfizer labeling page.

Venlafaxine HCL

Teva Pharmaceuticals is a leading producer of Venlafaxine HCl, introducing the first generic version of Effexor XR^® in the United States in 2010, which was awarded a 180-day period of marketing exclusivity. This generic version was launched 7 years ahead of the patent expiration, significantly reducing healthcare costs. Venlafaxine HCl, an SNRI, is used to treat depression, generalized anxiety disorder, social anxiety disorder, and panic disorder. The medication is available in various doses, including 37.5 mg, 75 mg, and 150 mg extended-release capsules. Teva's Venlafaxine HCl has been a crucial addition to the market, given the brand product's annual sales of approximately $2.75 billion in the U.S. For more details on Venlafaxine HCl by Teva, you can visit their website.

Venlafaxine ER

Venlafaxine ER (Mylan) is a highly regarded formulation of the selective serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine, known for its effectiveness in treating major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. The extended-release formulation allows for once-daily dosing, providing a smoother onset of action and fewer adverse effects compared to the immediate-release form. In China, the extended-release form, such as Effexor XR, held about 50% of the market share in terms of sales value in 2020. Venlafaxine ER is well-absorbed after oral administration, with peak plasma concentrations occurring within a few hours, and full therapeutic effects typically seen within six to eight weeks. The product is available in various strengths, including 37.5 mg, 75 mg, and 150 mg capsules. For more detailed patient tips on Venlafaxine, visit their website.

Venlafaxine ER

Venlafaxine ER by Aurobindo Pharma USA is a highly regarded generic version of Effexor XR, approved by the US FDA for treating major depressive disorder (MDD) and anxiety disorders. It is available in multiple strengths of 37.5 mg, 75 mg, and 150 mg, and its market size was approximately $2.4 billion for the twelve months ending September 2010. Aurobindo Pharma received tentative approval for this product under Paragraph IV certification, although the launch was delayed due to litigation. The drug held a significant share in the antidepressants market, with Effexor XR accounting for 36% of the market in 2008, valued at $3.93 billion. Aurobindo Pharma's version is part of a larger trend where Indian pharmaceutical companies are tapping into the generic US drug market, particularly with the expiration of patents on major drugs. For more detailed information, please visit the DailyMed website.

Venlafaxine ER

Venlafaxine ER, produced by Sun Pharma, is a highly regarded formulation of the selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Sun Pharma, with its global presence and strong manufacturing capabilities across 43 locations, ensures high-quality production. The company's extensive experience and large market share, with around 70% of its revenue generated from international markets, particularly in the US and India, underscore its reliability. Venlafaxine ER, available in various dosages such as 37.5 mg, 75 mg, and 150 mg, is known for its efficacy in restoring the brain's natural chemical balance. The extended-release formulation, introduced in 1997, offers a convenient once-daily dosing option. For more detailed insights into the market dynamics, explore the Venlafaxine Hydrochloride Market Report.

Venlafaxine ER

Venlafaxine ER, produced by Lupin Pharmaceuticals, is a highly regarded generic version of the antidepressant Effexor XR. In 2011, Indian pharmaceutical firms, including Lupin, received FDA approval to launch generic versions of Effexor, which held a 36% share in the antidepressants market in 2008 with $3.93 billion in sales. Lupin Pharmaceuticals has established a strong presence in the US market, with its generic products ranking high in market share; for instance, 20 out of 41 generic products marketed by Lupin in the US ranked No. 1 by market share in 2012. The company's US subsidiary, Lupin Pharmaceuticals, Inc., has grown significantly, reporting a 17.9% growth in US generics business revenues in FY 2012. Venlafaxine ER is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder in adults.

Venlafaxine ER

Dr. Reddy's Laboratories is a leading producer of Venlafaxine ER tablets, which are therapeutically equivalent to Venlafaxine Extended-Release Tablets approved by the U.S. Food and Drug Administration (USFDA). These tablets are available in 150 mg and 225 mg strengths and come in bottle count sizes of 30 and 90. The brand and generic had U.S. sales of approximately $51 million for the twelve months ending in October 2021, according to IQVIA Health. Dr. Reddy's robust regulatory compliance and successful launches have driven significant growth, with the company delivering a 4% sales CAGR over FY19-21. This underscores Dr. Reddy's commitment to quality and efficacy in their pharmaceutical products. For more details on Dr. Reddy's launch of Venlafaxine ER tablets in the US market.

Venlafaxine ER

Venlafaxine ER, produced by Cipla USA, is a prominent player in the antidepressant market, particularly for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder in adults. This medication, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is available in various formulations, including extended-release tablets and capsules, which help in reducing the pill burden for patients. The global venlafaxine market, dominated by North America due to high disposable income and advanced healthcare infrastructure, is expected to grow at a CAGR of 4% from 2022 to 2029. Venlafaxine ER is prescribed once daily with food and should be taken whole to maintain its extended-release properties. The product is part of a larger market that saw significant growth, with the antidepressants market valued at USD 19.92 Billion in 2023 and projected to reach USD 37.44 Billion by 2032.

Venlafaxine HCL

Venlafaxine HCL, produced by Zydus Pharmaceuticals, is a prominent player in the global market, known for its high-quality extended-release capsules. In 2023, the 37.5mg segment of Venlafaxine Hydrochloride Extended Release Capsules accounted for a significant share and is projected to experience substantial growth. Zydus Pharmaceuticals, along with other key companies like Teva and Pfizer, focuses on strategic expansions and product portfolio strengthening. The market is driven by increasing demand for treatments of major depressive disorder, generalized anxiety disorder, and panic disorder, with the hospital segment expected to expand at a significant CAGR. The global Venlafaxine Hydrochloride market is anticipated to witness a notable CAGR from 2024 to 2031.

Venlafaxine ER

Venlafaxine ER, produced by Torrent Pharmaceuticals, is a prominent player in the venlafaxine market, known for its efficacy in treating major depressive disorder, generalized anxiety disorder, and social anxiety disorder. The venlafaxine market, which includes Venlafaxine ER, is expected to grow at a CAGR of 4% from 2022 to 2029, driven by the increasing prevalence of anxiety and depression, as well as a rising geriatric population. In 2023, the venlafaxine market was valued at $3.24 billion, with North America dominating due to well-developed healthcare infrastructure and high disposable income. Venlafaxine ER, as an extended-release formulation, offers the convenience of once-daily dosing, enhancing patient compliance. The market is also influenced by growing government initiatives and increasing research and development activities. For more information, please visit the Venlafaxine ER product page on Torrent Pharmaceuticals' website.